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Abstract
Purpose:  To  compare  contrast  sensitivity  (CS)  in  multi-transfused  -thalassemia  patients  who
received  deferoxamine  with  those  who  received  Osveral.
Methods:  In  this  cross  sectional  study  a  total  of  60  -thalassemia  patients  (30  used  deferoxam-
ine and  30  used  deferasirox)  were  regarded  as  case  group  and  30  age  and  sex  matched  healthy
subjects  were  selected  as  control  group.  All  subjects  had  a  set  of  examinations  including  refrac-
tion, visual  acuity,  Biomicroscopy,  ophthalmoscopy  and  CS.  Contrast  threshold  was  assessed  with
the use  of  Freiberg  visual  acuity  and  contrast  test  under  the  mesopic  light  condition  for  three
frequencies;  1,  5,  15  cpd.  All  data  analysis  was  performed  using  SPSS,  version  17.
Results:  In  visual  acuity  tests,  thalassemic  patients  did  not  have  any  problem.  Contrast  thresh-
old was  higher  in  thalassemic  patients  who  infuse  deferoxamine  (1.87  ±  0.63,  1.46  ±  0.81,
and 2.96  ±  1.68  in  1,  5,  and  15  cpd,  respectively)  than  that  of  those  who  intake  deferasirox
(1.74 ±  0.80  (P  =  0.743),  0.99  ±  0.74  (P  =  0.047),  and  2.42  ±  1.36  (P  =  0.321)  for  1,  5,  and  15  cpd,
respectively),  and  also  than  healthy  patients  (1.33  ±  0.58  (P  =  0.009),  0.95  ±  0.68  (P  =  0.022),
and 2.24  ±  1.23  (P  =  0.135)  for  1,  5,  and  15  cpd,  respectively).  Comparing  those  who  used
deferasirox  with  healthy  subjects,  contrast  threshold  was  higher  in  deferasirox  group  at  all
special frequencies  (P  >  0.05).  No  signiﬁcant  relationship  was  observed  between  CS  values  and
duration of  transfusion,  serum  ferritin  concentration  and  dose  of  chelation  therapy  (P  >  0.05).
Conclusions:  CS  tests  can  detect  visual  disturbance  in  thalassemic  patients  before  the  impair-
ment of  visual  acuity.  It  is  suggested  that  CS  tests  be  included  in  their  regular  eye  examination.
© 2018  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).∗ Corresponding author at: Department of Optometry, School of Paramedical Science, Mashhad University of Medical Sciences, Mashhad,
ran.
E-mail address: opt heydarian@yahoo.com (S. Heydarian).
ttps://doi.org/10.1016/j.optom.2018.01.002
888-4296/© 2018 Spanish General Council of Optometry. Published by Elsevier Espan˜a, S.L.U. This is an open access article under the CC
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Contrast  sensitivity  in  -thalassemia  patients  169
PALABRAS  CLAVE
Umbral  de  contraste;
-Talasemia;
Deferoxamina;
Deferasirox
Comparación  de  la  sensibilidad  de  contraste  en  los  pacientes  con  -Talasemia
tratados  con  Deferoxamina  o  Deferasirox
Resumen
Objetivo:  Comparar  la  sensibilidad  de  contraste  (SC)  en  pacientes  multitrasfundidos  con  -
talasemia  y  tratados  con  deferoxamina  u  Osveral.
Métodos:  En  este  estudio  transversal,  un  total  de  60  pacientes  con  -talasemia  (30  tratados  con
deferoxamina  y  30  con  deferasirox)  fueron  considerados  como  grupo  de  estudio,  y  30  sujetos
sanos pareados  por  edad  y  sexo  fueron  seleccionados  como  grupo  control.  A  todos  los  sujetos  se
les realizó  una  serie  de  exámenes  que  incluyeron  refracción,  agudeza  visual,  biomicroscopía,
oftalmoscopía  y  SC.  El  umbral  de  contraste  se  valoró  mediante  la  prueba  de  agudeza  visual  y
contraste  de  Freiberg,  en  condiciones  de  visión  mesópica  para  tres  frecuencias:  1,  5  y  15  cpd.
Todos los  análisis  de  los  datos  se  realizaron  utilizando  SPSS,  versión  17.
Resultados:  En  las  pruebas  de  agudeza  visual  los  pacientes  con  talasemia  no  tuvieron  ningún
problema. El  umbral  de  contraste  fue  superior  en  los  pacientes  con  talasemia  a  quienes  se
infundió deferoxamina  (1,87±0,63,  1,46±0,81  y  2,96±1,68  en  1,  5  y  15  cpd,  respectivamente)
que en  los  pacientes  tratados  con  deferasirox  (1,74±0,8  (P=0,743),  0,99±0,74  (P=0,047)  y
2,42±1,36 (P=0,321)  para  1,  5  y  15  cpd,  respectivamente),  y  también  en  los  pacientes  sanos
(1,33±0,58 (P=0,009),  0,95±0,68  (P=0,022)  y  2,24±1,23  (P=0,135)  para  1,  5  y  15  cpd,  respecti-
vamente).  Al  comparar  los  pacientes  tratados  con  deferasirox  y  los  sujetos  sanos,  el  umbral  de
contraste fue  superior  en  el  grupo  de  deferasirox  para  todas  las  frecuencias  especiales  (P>0,05).
No se  observó  una  relación  signiﬁcativa  entre  los  valores  de  SC  y  la  duración  de  la  trasfusión,
la concentración  de  ferritina  sérica  y  la  dosis  de  la  terapia  de  quelación  (P>0,05).
Conclusiones:  Las  pruebas  de  SC  pueden  detectar  la  alteración  visual  en  los  pacientes  con
talasemia  con  anterioridad  al  deterioro  de  la  agudeza  visual.  Sugerimos  la  inclusión  de  las
pruebas de  SC  en  su  examen  ocular  regular.
© 2018  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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Thalassemia  which  is  one  of  the  most  common  sever  genetic
blood  disorders  can  lead  to  different  ocular  involvements.1,2
Ocular  ﬁndings  in  these  patients  may  correlate  to  disease
itself,  iron  overload  due  to  regular  blood  transfusion  or
chelating  agents  used  to  reduce  iron  store  in  their  body.3
Since  1970,  iron  chelation  therapy  has  been  used  to
reduce  iron  overload  in  thalassemic  patients.4 Deferoxamine
(DFO,  Desferal
®
)  is  the  oldest  iron  chelator  which  should  be
injected  subcutaneously  usually  in  the  duration  of  8--12  h.
Injection  of  DFO  is  its  main  problem.  So  in  recent  years
some  oral  chelators  such  as  deferiprone  and  deferasirox
were  introduced.5,6
Ocular  complications  of  thalassemia  and  its  therapeu-
tic  modalities  has  been  reported  by  many  sources.1,3,7,8 But
there  are  only  few  studies  that  evaluate  contrast  sensitiv-
ity  in  these  patients.9--11 Impaired  contrast  sensitivity  in  the
presence  of  normal  visual  acuity  can  detect  early  changes
in  the  visual  system  of  these  patients.  To  our  knowledge,  no
study  has  been  done  to  compare  contrast  sensitivity  in  tha-
lassemia  major  patients  who  used  different  chelator  agents.
Gartaganis  et  al.  in  2000  investigated  contrast  sensitivity
function  in  -thalassemia  major  patients  treated  by  reg-
ular  blood  transfusion  and  subcutaneous  infusion  of  DFO.
They  used  the  Vector  Vision  CSV-1000  contrast  sensitivity
test  and  conclude  that  contrast  sensitivity  function  in  all
T
r
p
i-thalassemia  patients  was  signiﬁcantly  lower  than  normal
ubjects.10 Spyridon  et  al.  in  2010  used  B-VAT  II  SG  mentor
isual  acuity  tester  to  measure  contrast  sensitivity  in  -
halassemia  major  patients  and  found  signiﬁcant  difference
etween  contrast  sensitivity  of  thalassemic  and  normal  sub-
ects  in  special  frequencies  of  2,  3,  and  6  cycles  per  degree
cpd).11
According  to  high  prevalence  of  -thalassemia  in  Iranian
opulation,  particularly  in  north  of  Iran12 and  its  ocular  side
ffects  which  inﬂuence  their  quality  of  life,  evaluation  of
ontrast  sensitivity  of  these  patients  using  cheap,  simple
nd  reliable  test  to  identify  early  changes  in  their  ocular
ystem  is  fundamental.
The  primary  objective  of  this  study  was  to  compare  con-
rast  sensitivity  in  multi-transfused  -thalassemia  patients
ho  received  subcutaneous  DFO  with  those  who  received
sveral  (an  Iranian  made  deferasirox)  and  normal  subjects.
e  also  investigated  the  correlation  of  contrast  sensitivity
ith  serum  ferritin  level,  duration  of  blood  transfusion  and
osage  of  chelation  therapy.
ethodshis  cross  sectional  study  was  carried  out  in  the  thalassemic
esearch  center  of  Mazandaran  province,  Iran.  Thalassemic
atients  in  Mazandaran  are  all  registered  in  this  center
n  order  to  receive  treatment.  Study  participants  were
1 A.  Ghazanfari  et  al.
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Table  1  Spherical  and  cylindrical  refractive  errors  in  two
thalassemic  and  control  groups.1
Sphere  Cylinder
Median(IQR2=Q1-Q3)  Median(IQR  =  Q1-Q3)
Desferal  group 0.00(0.00-0.25)  -0.25(-0.50-0.00)
Osveral  group  0.00(0.00-0.50)  0.00(-0.31-0.00)
Control  group  0.00(0.00-0.00)  -0.25(-0.50-0.00)
P-value  0.005  0.478
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elected  with  simple  random  sampling  method  from  the  list
f  thalassemic  patients  with  the  use  of  computerized  table.
nformed  written  consent  was  obtained  from  all  partici-
ants  after  a  detailed  explanation  of  the  nature  of  the  study
ccording  to  the  code  of  ethics  in  the  declaration  of  Helsinki
rotocol.  Selected  participants  were  visited  by  hematolo-
ist  and  those  with  no  diabetes  or  other  systemic  disease
ho  received  chelator  agents  (DFO  or  deferasirox)  for  at
east  2  years  were  referred  for  ophthalmic  and  optometric
valuation.
An  ophthalmologist  examined  anterior  and  posterior  seg-
ents  of  the  eye  with  the  use  of  slit  lamp  (Model  BQ  900:
aag  Streit,  Bern,  Switzerland)  and  ophthalmoscope  (Oph-
halmoscope,  Heine  Beta  200,  Germany)  and  those  with  any
phthalmic  pathology,  aphakia,  strabismus,  corneal  and  lens
pacities,  history  of  ocular  surgery,  history  of  ocular  trauma
nd  pathologic  myopia  were  excluded.
Then  an  optometrist  began  optometric  examinations.
ncorrected  visual  acuity  (UCVA)  was  measured  monocu-
arly  using  the  Snellen  chart  at  6  m.  Refraction  was  measured
sing  the  autorefractometer  (Topcon  RM8800)  and  checked
ith  a  Heine  streak  retinoscope  (HEINE  Optotechnik).  Those
ith  UCVA  worse  than  20/20  had  subjective  refraction  and
hen  best  corrected  visual  acuity  (BCVA)  was  recorded.
hose  with  BCVA  worse  than  20/20  and  those  with  spherical
efractive  error  of  more  than  1.5  diopter  (D)  and  astigmatism
reater  than  1  D  were  excluded  from  the  study.
Finally,  60  patients  with  -thalassemia  (30  used  DFO
nd  30  used  deferasirox)  ranging  in  age  between  20  to  30
ears  and  30  age  and  sex  matched  healthy  subjects  were
nrolled  for  the  study.  Healthy  subjects  were  selected  ran-
omly  amongst  the  staff  of  the  thalassemia  research  center.
ontrast  sensitivity  test  was  done  for  all  selected  subjects.
ontrast  threshold  was  measured  for  each  eye  with  the
reiberg  visual  acuity  and  contrast  test  (FrACT  version  3.7.1)
nder  mesopic  light  condition  for  three  frequencies;  1,  5,
5  cpd.
FrACT  is  a  computer  program  that  uses  eight  alter-
ative  force  choices  and  the  best  parameter  estimation
y  sequential  testing  (PEST)  algorithm  for  threshold
etermination.13,14 It  enables  automatic  and  observe  inde-
endent  determination  of  contrast  threshold  at  different
pecial  frequencies  using  sinusoidal  gratings  or  special  opto-
ype  size.  In  this  study,  gratings  were  presented  in  8
ifferent  orientations.  The  patient  tell  the  perceived  direc-
ion  of  gratings  and  the  investigator  entered  the  response.
wenty-four  trials  comprised  one  run  and  two  runs  were
aken  for  each  condition.  At  the  end  of  the  test,  contrast
hreshold  was  computed  in  percent  and  showed  on  the
creen.
Contrast  threshold  was  tested  monocularly  at  a distance
f  4  m.  In  those  with  UCVA  worse  than  20/20,  contrast  sen-
itivity  evaluation  was  performed  using  carefully  cleansed
rial  lenses  (Oculus,  Wetzler,  Germany).
Descriptive  and  inferential  data  analysis  were  carried
ut  using  SPSS.17  software  (SPSS  for  Windows,  SPSS  Inc.,
hicago,  IL,  USA).  Kolmogorov--Smirnov  test  for  normality
ndicated  that  the  distribution  of  spherical  and  cylin-
rical  refractive  errors  was  not  normal  and  therefore
on-parametric  tests  were  used  for  statistical  analysis  of
hese  parameters.  Median  test,  independent  sample  T  Test,
ne-way  ANOVA  and  Pearson  correlation  were  used  where
c
t
a1 Median test used for analysis.
2 IQR = (Q1-Q3) = Interquartile range.
pplicable.  A  statistical  signiﬁcant  difference  was  consid-
red  for  P <  0.05.
esults
n  this  study,  60  thalassemic  patients  were  studied  includ-
ng  thirty  patients  from  desferal  group  and  30  from  Osveral
roup.  As  contrast  thresholds  in  the  right  and  left  eye
ere  correlated  (Pearson  correlation;  r  =  0.847,  P  =  0.000),
he  data  from  the  right  eye  were  considered.  The  mean
ge  of  thalassemic  patients  in  Desferal  and  Osveral  groups
ere  24.33  ±  3.44  and  23.70  ±  3.39,  respectively.  The  con-
rol  group  included  30  healthy  subjects  with  the  mean  age
f  24.70  ±  3.46.  The  age  of  included  subjects  in  case  and
ontrol  groups  ranged  from  20  to  30  years  old.  There  was
o  signiﬁcant  difference  for  sex  and  age  between  groups
P  =  0.731,  P  =  0.524,  respectively).
Table  1  shows  median  and  interquartile  range  (IQR)  of
pherical  and  cylindrical  refractive  errors  in  the  two  tha-
assemic  and  control  groups.  Median  test  was  used  for
esting  whether  study  groups  differ  in  their  median  value
r  not.  According  to  the  table,  signiﬁcant  difference  was
ound  between  spherical  refractive  errors  of  three  groups
P  =  0.005),  but  no  signiﬁcant  difference  was  found  in  cylin-
rical  refractive  errors  (P  =  0.478).
All  thalassemic  patients  were  asymptomatic  and  oph-
halmic  examinations  did  not  revealed  any  pathological  and
tructural  problem  in  their  ocular  system.  The  mean  ±  SD
alues  for  best  corrected  visual  acuity  was  1  min  of  arc  in  all
articipants.
Table  2  shows  the  characteristics  of  thalassemic  patients
ased  on  the  type  of  chelator  they  received.
The  mean  ±  SD  contrast  threshold  of  all  participants  are
iven  in  Table  3. Contrast  threshold  was  evaluated  for  three
patial  frequencies  (1,  5,  and  15  cpd).  One-way  ANOVA  test
howed  a  signiﬁcant  difference  between  contrast  threshold
f  patients  in  Desferal  and  control  groups  in  all  evaluated
pecial  frequencies.  Also,  contrast  threshold  of  Desferal
roup  for  all  special  frequencies  was  higher  than  that  of
sveral  group,  although  the  difference  was  not  statistically
igniﬁcant  for  1  and  15  cpd.  In  the  comparison  of  contrast
hreshold  in  those  who  used  deferasirox  with  healthy  sub-
ects,  contrast  threshold  was  higher  in  deferasirox  group  at
ll  special  frequencies,  but  the  difference  was  not  signiﬁ-
ant.
Table  4  represents  the  Pearson  correlation  of  contrast
hreshold  with  serum  ferritin  level,  dose  of  chelation  ther-
py  and  duration  of  blood  transfusion.  According  to  the
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Table  2  Comparison  of  characteristics  of  thalassemic  patients  based  on  the  type  of  chelator  they  received1
Duration  of  blood  transfusion  (Year)  Serum  ferritin  level  (mg/L)  Chelator  dosage  (mg/kg/day)
Desferal  Group  22.4  ±  4.14  (14-29)  2575  ±  1678(400-7000)  36.82  ±  9.56  (16-65)
Osveral Group  18.53  ±  3.86  (10-28)  1951  ±  1336  (575-7000)  24.13  ±  5.59  (8-35)
P-Value 0.000  0.11  0.000
1 Independent sample T Test used for analysis
Table  3  Mean  contrast  threshold  of  both  thalassemic  and  healthy  subjects.1
Special  Frequencies  Study  Group  Contrast  threshold  mean  ±  SD  [Range2]  P-value
Desferal  &
Osveral
Desferal  &
Normal
Osveral  &
Normal
1  cpd  Desferal  1.87  ±  0.63  [0.51-3.44]  0.743  0.009  0.061
Osveral 1.74  ±  0.8  [0.51-3.91]
Normal  1.33  ±  0.58  [0.51-2.79]
5 cpd  Desferal  1.46  ±  0.81  [0.50-2.95]  0.047  0.022  0.949
Osveral 0.99  ±  0.74  [0.50-2.97]
Normal  0.95  ±  0.68  [0.51-2.54
15 cpd  Desferal  2.96  ±  1.68  [0.51-6.88]  0.321  0.135  0.879
Osveral 2.46  ±  1.36  [0.76-6.54]
Normal  2.24  ±  1.23  [0.51-5.98]
1 Determined by one-way ANOVA and Tukey post hoc test.
2 Range = [Min-Max].
Table  4  The  Correlation  of  contrast  threshold  with  serum  ferritin  level,  dose  of  chelation  therapy  and  duration  of  blood
transfusion.1
Serum  ferritin  level  Duration  of  blood  transfusion  Chelator  dose
P r  p  r  p  r
Contrast  threshold  Desferal  1  cpd  0.98  .004  0.03  -0.39  0.47  0.136
5 cpd  0.06  0.346  0.18  0.246  0.19  0.246
15 cpd  0.22  0.230  0.90  0.023  0.42  0.150
Osveral 1  cpd  0.54  0.115  0.35  0.174  0.24  0.219
5 cpd  0.31  0.191  0.70  0.071  0.29  0.199
15 cpd  0.17  0.257  0.27  0.204  0.17  0.254
w
a
o
o
o
G
t
v
c
d
p
s1 Pearson Correlation.
table,  no  signiﬁcant  correlation  was  found  between  contrast
threshold  and  these  parameters.
Discussion
Contrast  sensitivity  has  been  considered  as  an  important
indicator  of  visual  function  by  some  researchers  and  it  is
claimed  that  its  evaluation  can  better  discriminate  oph-
thalmic  disorders  compared  to  Snellen  visual  acuity.15,16 As
the  results  of  this  study  showed,  contrast  threshold  was
higher  in  patients  with  major  thalassemia  who  infuse  DFO
than  that  of  those  who  intake  deferasirox  and  also  healthy
patients  at  all  spatial  frequencies.  In  the  comparison  of  con-
trast  threshold  in  those  who  used  deferasirox  with  healthy
subjects,  contrast  threshold  was  higher  in  deferasirox  group
at  all  special  frequencies,  but  the  difference  was  not  sig-
niﬁcant.  While  in  conventional  visual  acuity  tests  measured
d
t
i
cith  the  Snellen  chart,  thalassemic  patients  did  not  have
ny  problem.  No  statistically  signiﬁcant  relationship  was
bserved  between  contrast  sensitivity  values  and  duration
f  transfusion,  mean  serum  ferritin  concentration  and  dose
f  chelation  therapy.
Previous  studies  have  also  conﬁrmed  similar  ﬁndings;
artaganis  et  al.  have  found  that  contrast  sensitivity  func-
ion  in  all  beta-thalassemic  patients  with  normal  Snellen
isual  acuity  was  signiﬁcantly  lower  compared  to  the  normal
ontrol  subjects  for  all  spatial  frequencies  tested.10 Spyri-
on  et  al.  also  reported  reduced  contrast  sensitivity  values  in
atients  with  major  thalassemia  than  the  values  for  normal
ubjects  for  frequencies  of  2,  3  and  6  cpd.11
Ocular  complications,  such  as  lens  opacity,  macular
egeneration,  retinal  vascular  changes  and  RPE  degenera-
ion  have  been  reported  in  patients  with  major  thalassemia
n  previous  studies.1,3,7,8,17 The  mechanism  is  not  exactly
lear,  some  researchers  believe  that  ocular  abnormalities
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ere  mainly  because  of  iron  overload  and  not  secondary
o  chelation  therapy  while  others  claim  that  chelator
dministration,  especially  DFO,  has  toxic  effects  and  can
ffect  the  eye  in  many  ways.3 Also,  unstable  blood
emoglobin  values  in  spite  of  periodic  blood  transfusion  can
ause  chronic  retinal  hypoxia  and  damage  function  of  the
etinal  cells.10
In  the  current  study,  we  did  not  include  those  with
ny  pathologic  eye  problems  or  systemic  diseases,  such  as
iabetes  which  can  adversely  affect  visual  system.  It  is
laimed  that  in  diabetic  patients  due  to  disruption  of  the
lood  retinal  barrier,  DFO  is  able  to  cross  to  retina  more
han  in  normal  patients  and  consequently  can  cause  more
oxic  problems.18,19 On  the  other  hand,  we  exclude  tha-
assemic  patients  with  high  refractive  errors,  especially  high
yopia.  It  seems  that  in  these  patients  due  to  changes  in
ruch  layer,  iron  deposition  would  be  higher  and  subse-
uently  more  side  effect  is  expected.20 It  should  be  noted
hat,  similar  to  previous  studies,  despite  the  lack  of  obvi-
us  pathological  and  structural  changes  in  the  ocular  system
f  our  selected  thalassemic  patients,  their  contrast  sen-
itivity  was  considerably  lower  than  in  healthy  subjects,
specially  in  those  who  infuse  DFO.  However,  although  we
o  not  ﬁnd  any  obvious  ocular  pathology  in  our  selected
atients,  previous  studies  indicated  that  they  may  reveal
ome  abnormalities  with  the  use  of  electro-diagnostic  tests,
uorescein  angiography  or  tests  such  as  perimetery.1,3,21 For
nstance,  Gartaganis  et  al.  did  not  found  any  problem  in
lit  lamp  examination  of  their  patients  but  angiod  streak
nd  RPE  degeneration  were  revealed  in  13%  of  their  sub-
ects  with  the  use  of  ﬂuorescein  angiography.  They  also
eported  that  contrast  sensitivity  loss  in  those  who  revealed
cular  pathology  with  the  use  of  ﬂuorescein  angiography
as  higher  than  that  of  those  who  do  not  showed  any
roblem.10
The  result  of  our  study  showed  a  signiﬁcant  difference
etween  contrast  sensitivity  of  thalassemic  patients  who
sed  different  chelator  drugs.  To  our  knowledge,  this  is
he  ﬁrst  study  that  compare  contrast  sensitivity  in  tha-
assemic  patients  using  different  chelator  agents.  In  a
revious  study,  we  evaluate  ocular  abnormalities  in  tha-
assemic  patients  who  used  different  chelator  drugs.  In
hat  study,  in  order  to  evaluate  the  effect  of  different
ype  of  chelators,  thalassemia  patients  were  divided  into
hree  groups  based  on  the  type  of  chelators  they  received:
roup  A  received  blood  transfusion  and  subcutaneous  DFO,
roup  B  blood  transfusion  combined  with  subcutaneous
FO  and  oral  deferiprone,  and  Group  C  blood  transfusion
long  with  Osveral.  Although  no  signiﬁcant  difference  was
ound  between  the  prevalence  of  different  type  of  ocu-
ar  abnormalities  among  three  thalassemic  groups  in  that
tudy,  among  evaluated  ocular  abnormalities,  RPE  degen-
ration  was  slightly  higher  in  those  who  used  desferal  in
omparison  to  those  who  used  Osveral.1 In  our  present
tudy,  contrast  sensitivity  in  desferal  group  was  consid-
rably  lower  than  that  of  Osveral  group.  More  reduction
f  contrast  sensitivity  in  those  who  used  desferal  conﬁrm
hat  they  may  reveal  some  abnormalities  in  more  detailed
xaminations.
There  are  several  studies  that  investigate  the  relation-
hip  between  the  dose  of  chelator  agents,  mean  serum
erritin  level  and  the  number  of  blood  transfusions  with
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cular  problems.1,8,10,22 In  this  study,  we  did  not  observe  any
elationship  between  duration  of  blood  transfusion,  chela-
or  dose  and  serum  ferritin  level  with  contrast  sensitivity,
hich  was  similar  to  Gartaganis  ﬁndings.  They  conclude  that
he  main  reason  for  contrast  sensitivity  loss  could  be  chronic
etinal  hypoxia  and  other  factors  such  as  duration  of  transfu-
ions,  the  duration  of  chelator  therapy  and  the  serum  ferritin
oncentrations  are  of  lesser  importance.10 In  our  previous
tudy  on  another  group  of  thalassemic  patients,  we  found
 signiﬁcant  positive  correlation  between  the  prevalence
f  ocular  abnormalities  and  number  of  blood  transfusions
ut  not  with  mean  serum  ferritin  level  and  dose  of  chela-
or  agents.1 However,  considering  different  age  range  of  the
articipants  in  different  studies,  it  is  difﬁcult  to  make  an
ccurate  comparison.
However,  despite  widespread  claims  of  the  effective-
ess  of  DFO  dosage  on  visual  function,22 we  do  not  ﬁnd
ny  correlation  between  doses  of  chelator  agents  and  con-
rast  sensitivity  reduction.  This  could  be  due  to  low  dose
f  chelator  that  our  patients  received.  Cohen  et  al.  indi-
ated  that  DFO  doses  lower  than  50  mg/kg/day  cannot  cause
tructural  eye  problems  and  only  may  lead  to  hearing  loss.23
inety  eight  percent  of  our  subjects  received  lower  than
0  mg/kg/day  of  chelators.
Our  study  has  some  limitations;  in  this  study  those  who
ere  taking  Osveral  were  on  DFO  previously,  so  loss  of  con-
rast  sensitivity  can  be  related  to  their  previous  treatment.
lso,  due  to  the  limited  number  of  cases  and  the  short
ime  that  they  intake  Osveral,  we  could  not  fully  evaluate
ffect  of  Osveral  on  contrast  sensitivity  function  of  these
atients.  Also,  we  do  not  evaluate  and  exclude  patients  with
ry  eye.  As  there  is  evidence  about  the  degree  of  associa-
ion  between  thalassemia  and  dry  eye,1 which  could  have
ome  effects  on  contrast  sensitivity  results,  it  was  better  to
xclude  those  with  dry  eye.
As  we  know,  in  many  ophthalmic  disorders  contrast  sen-
itivity  tests  can  detect  visual  disturbances  before  the
mpairment  of  visual  acuity.  According  to  this  issue,  it  is  sug-
ested  that  contrast  sensitivity  tests  be  included  in  regular
ye  examination  of  thalassemic  patients  and  in  the  event  of
iagnosis  any  reduction  in  contrast  sensitivity,  it  is  better
o  refer  patients  to  hematologist  to  evaluate  the  possibil-
ty  of  changing  their  treatment  regimen  and  prevent  further
omplications.
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